The global mobile health (mHealth) apps and solutions market is projected to experience significant growth, with a compound annual growth rate (CAGR) of 18.18% ...

Patients with presbyopia experienced improvements in near vision after treatment with Brimochol PF in a second phase 3 ...

A novel presbyopia drop improves near vision using pupillary constriction to create a pinhole effect, while allowing good distance vision.

In a phase 3 trial, Tenpoint Therapeutics’ eye drop—a combination of carbachol and brimonidine—improved vision for patients ...

Tenpoint Therapeutics, Inc., a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye, today reported positive topline results from BRIO-II, ...

Tenpoint Therapeutics, Inc., a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate ...

Newly generated human embryonic stem cell‐derived atrial‐like cardiomyocytes resemble human atrial cardiomyocytes and prove to be a valuable model for pre‐clinical drug screenings to identify ...

A central component of the merged portfolio is BRIMOCHOL PF, a once-daily, presbyopia-correcting eye drop. The product combines carbachol, a miotic agent, with brimonidine, an alpha2-agonist. 1 ...

Tenpoint and Visus merge to focus on aging-related ocular conditions, including presbyopia, cataracts, and geographic atrophy. BRIMOCHOL PF, a presbyopia-correcting eye drop, combines carbachol and ...